We compared the efficacy of atorvastatin with simvastatin according to cholesteryl ester transfer protein (CETP) and adenosine triphosphate-binding cassette transporter A1 (ABCA1) genes. Patients treated with atorvastatin (n = 254) or simvastatin (n = 332) were genotyped for CETP (TaqIB and I405V) and ABCA1 (R219K) genetic variants. For genotype B1B2, atorvastatin compared with simvastatin treatment resulted in a greater decrease in total cholesterol (35.4% vs 31.6%, P = .035) and a lower increase in high-density lipoprotein cholesterol (2% vs 8%, P = .05). For genotype B2B2, atorvastatin compared with simvastatin treatment resulted in a lower decrease in low-density lipoprotein cholesterol (31.85 vs 42%, P = .029). For genotypes RR and KK, atorvastatin compared with simvastatin treatment resulted in a greater decrease of triglycerides (27% vs 17% and 35% vs 15%, respectively; P = .02 for all comparisons). The TaqIB and R219K (opposite to I405V) gene polymorphisms seem to modify the response to lipid-lowering therapy with simvastatin or atorvastatin treatment.
YamashitaSHiranoKSakaiNMatsuzawaY. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta. 2000;1529(1-3):257–275.
2.
KolovouGDAnagnostopoulouKKKaryofillisP. Cholesteryl ester transfer protein gene polymorphisms and severity of coronary stenosis. Clin Invest Med. 2006;29(1):14–19.
3.
KolovouGVasiliadisIKolovouV. The role of common variants of the cholesteryl ester transfer protein gene in left main coronary artery disease. Lipids Health Dis. 2011;10:156.
4.
de KeyserCEEijgelsheimMHofmanA. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. Pharmacogenomics J. 2011;11(1):72–80.
5.
DeanMHamonYChiminiG. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001;42(7):1007–1017.
6.
Frikke- SchmidtRNordestgaardBGJensenGBTybjaerg-HansenA. Genetic variation in ABC transporter A1 contributes to HDL-cholesterol in the general population. J Clin Invest. 2004;114(9):1343–1353.
7.
AnagnostopoulouKKolovouGKostakouP. Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother. 2007;8(15):2459–2463.
8.
KolovouGMihasCAnagnostopoulouK. Cholesteryl ester transfer protein gene and effectiveness of lipid lowering of atorvastatin. Open Cardiovasc Med J. 2010;4:297–301
9.
GrundySMCleemanJIMerzCN. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation.2004;110(2):227–239.
10.
KolovouGAnagnostopoulouKKostakouP. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin Chem Lab Med. 2007;45(9):1190–1198.
11.
GudnasonVKakkoSNicaudV. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest.1999;29(2):116–128.
12.
TupitsinaTVSlominskyPAYeferevaYMPerovaNIAronovDMLimborskaSA. Linkage analysis by a transmission/Disequilibrium of Russian sibling pairs with coronary artery disease. Balkan J Med Genetics. 2007;10:43–54.
13.
FreemanDJGriffinBAHolmesAP. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors: associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb. 1994;14(3):336–344.
14.
PasdarAYadegarfarGCummingAWhalleyLSt ClairDMacLeodMJ. The effect of ABCA1 gene polymorphisms on ischaemic stroke and relationship with lipid profile. BMC Med Genet. 2007; 8:30.
15.
HassanzadehTFiroozraiMZonouzAEZavareheeAPaoliM. Taq1B polymorphism of cholesteryl ester transfer protein (CETP) gene in primary combined hyperlipidaemia. Indian J Med Res. 2009;129(3):293–298.
16.
CenarroAArtiedaMCastilloS. A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. J Med Genet. 2003;40(3):163–168.
17.
BarberMJMangraviteLMHydeCL. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One. 2010;5(3):e9763.
18.
HoenigMRWalkerPJGurnseyCBeadleKJohnsonL. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011;5(2):91–96.
19.
WeiKKZhangLRZhangYHuXJ. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. J Clin Pharm Ther. 2011;36(6):725–733.
20.
LiYPZhangLRJiaMHuXJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol. 2011;51(2):181–188.
21.
VooraDShahSHReedCR. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1(2):100–106.
22.
KolovouGDAnagnostopoulouKKSalpeaKDDaskalopoulouSSMikhailidisDP. The effect of statins on postprandial lipemia. Curr Drug Targets. 2007;8(4):551–560.
